Veteran’s Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life (KAP)

This observational cohort study (n=30) will explore how veterans aged 65 and older enrolled in VA healthcare perceive ketamine-assisted psychotherapy (KAP) for depression and end-of-life distress.

The study, conducted by the Albany Research Institute at Stratton VA Medical Center, will gather both qualitative and quantitative data through interviews and questionnaires.

Participants will complete symptom screening questionnaires and then take part in a recorded interview using a story-completion approach, where they respond to a scenario involving a fictitious veteran considering KAP for depression and later for end-of-life care. Researchers will analyse the responses to identify common themes, attitudes, and concerns. The findings aim to inform educational efforts and the potential implementation of KAP within the VA system.

Topic Depression Palliative Care Healthy Subjects
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

US Department of Veteran Affairs
The US Department of Veteran Affairs is playing an important role in the psychedelic renaissance by exploring and monitoring advancements in psychedelic therapies and the viability of these therapies for veterans with PTSD.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.